Tin tức & Cập nhật

A combination regimen comprising trifluridine/tipiracil (FTD/TPI) and bevacizumab demonstrates favourable efficacy and safety in individuals with metastatic colorectal cancer (mCRC) in the real-world BeTAS study presented at ASCO GI 2025.

Combined use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and pioglitazone may be a potentially useful strategy to ameliorate metabolic dysfunction–associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), according to a real-world study conducted by researchers from the University of Hong Kong and Queen Mary Hospital (QMH).